Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™ GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021 — Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, [….]
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
